Ovid Therapeutics, Inc. (OVID)
2.20
-0.14
(-5.98%)
USD |
NASDAQ |
Nov 20, 16:00
2.205
0.00 (0.00%)
After-Hours: 20:00
Ovid Therapeutics Enterprise Value : 290.94M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 290.94M |
| November 19, 2026 | 317.36M |
| November 18, 2026 | 302.26M |
| November 17, 2026 | 294.71M |
| November 16, 2026 | 328.68M |
| November 13, 2026 | 355.10M |
| November 12, 2026 | 356.99M |
| November 11, 2026 | 400.40M |
| November 10, 2026 | 404.17M |
| November 09, 2026 | 413.61M |
| November 06, 2026 | 413.61M |
| November 05, 2026 | 362.65M |
| November 04, 2026 | 392.85M |
| November 03, 2026 | 328.68M |
| November 02, 2026 | 326.80M |
| October 30, 2026 | 355.10M |
| October 29, 2026 | 358.88M |
| October 28, 2026 | 338.12M |
| October 27, 2026 | 302.26M |
| October 26, 2026 | 282.45M |
| October 23, 2026 | 283.39M |
| October 22, 2026 | 323.02M |
| October 21, 2026 | 341.89M |
| October 20, 2026 | 321.13M |
| October 19, 2026 | 285.28M |
| Date | Value |
|---|---|
| October 16, 2026 | 281.50M |
| October 15, 2026 | 302.26M |
| October 14, 2026 | 289.05M |
| October 13, 2026 | 289.05M |
| October 12, 2026 | 330.57M |
| October 09, 2026 | 340.01M |
| October 08, 2026 | 317.36M |
| October 07, 2026 | 321.13M |
| October 06, 2026 | 323.02M |
| October 05, 2026 | 317.36M |
| October 02, 2026 | 324.91M |
| October 01, 2026 | 334.34M |
| September 30, 2026 | 345.67M |
| September 29, 2026 | 364.78M |
| September 28, 2026 | 350.00M |
| September 25, 2026 | 338.91M |
| September 24, 2026 | 356.46M |
| September 23, 2026 | 370.32M |
| September 22, 2026 | 405.42M |
| September 21, 2026 | 396.18M |
| September 18, 2026 | 392.49M |
| September 17, 2026 | 394.34M |
| September 16, 2026 | 390.64M |
| September 15, 2026 | 396.18M |
| September 14, 2026 | 401.73M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.78M |
| Total Expenses (Quarterly) | 20.78M |
| EPS Diluted (Quarterly) | -0.1024 |
| Earnings Yield | -8.40% |
| Normalized Earnings Yield | -0.2227 |